Navigation Links
AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial

Cetrorelix showed good safety and tolerability profile Reduction of testosterone concentration was maintained above castration level Japanese partner Shionogi initiates Phase 2b trial

QUEBEC CITY, March 22, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. along with its Japanese partner Shionogi & Co., Ltd. today announced positive results for a Phase 2a trial with cetrorelix in benign prostatic hyperplasia (BPH) initiated in 2005 in Japan. Results showed that cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, was safe and well tolerated at all dosage regimens. Furthermore, Japanese patients responded to cetrorelix with a transient reduction of testosterone concentration in blood, which did not reach or remain at the castration level. Additionally, none of the dosage regimens tested caused a suppression of PSA levels. Finally, data generated with Japanese patients showed that the bioavailability of cetrorelix was similar to that observed in non-Japanese patients.

On the basis of this study, Shionogi initiated a 300-patient phase 2b study to assess primarily the efficacy of cetrorelix in BPH in Japanese patients.

"We are very pleased with these results which further confirm the positive data observed in prior clinical trials in BPH with cetrorelix in non-Asian patients", said Gilles Gagnon, President and CEO of AEterna Zentaris. "Shionogi's decision to initiate a Phase 2b trial in BPH combined with our own ongoing Phase 3 program with cetrorelix in this same indication, allows us to pursue the development of cetrorelix at an international level and represents an opportunity to potentially gain access to large markets worldwide."

Nippon Kayaku, the Company's other Japanese partner, has terminated its agreement with respect to their collaboration with the development of cetrorelix pamoate to focus solely in oncology.

About the Phase 2a trial'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Post Your Comments:
(Date:11/23/2009)...INTRICHMOND,Calif.,Nov.23/PRNewswire-FirstCall/--T...nouncedthatitisscheduledtomeetwiththeU.S.FoodandDr...ompleteResponseLetterregardingtheNewDrugApplicatio...ingualtablet).Aspreviouslyannounced,theCompleteRes...dicatedthattheFDAcouldnotapprovetheNDAinitspresent...
(Date:11/23/2009)...MBRIDGE,Mass.,Nov.23/PRNewswire/--LigonDiscovery,I...hnologytofinddrugsagainsthigh-valuetargets,todayan...anErrolB.DeSouzaasLigon,sExecutiveChairmanoftheBoa...ecutiveChairmanoftheBoard,"saidPatrickKleyn,Ligon,...,sbreadthofexperienceinthelifesciencesindustry--pa...
(Date:11/23/2009)...llowingtheFDAapprovalsoftwonewtherapiesforNon-Hodg...nupdatedtoincludeofatumumab(Azerra(TM),GlaxoSmithK...yticleukemia(CLL)andromidepsin(Istodax(R),Gloucest...withcutaneousT-celllymphoma(CTCL). ,, FORTWASHI...FDAapprovalshavepromptedtheNationalComprehensiveCa...
Breaking Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 1CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 2CEL SCI Corporation to Raise 2420 Million in Registered Direct Offering 57405 3Prescient Medical vProtect 28TM 29 Luminal Shield Receives North American Product Innovation of the Year Award from Frost 26 Sullivan 57403 1Prescient Medical vProtect 28TM 29 Luminal Shield Receives North American Product Innovation of the Year Award from Frost 26 Sullivan 57403 2PharmAbcine Closes USD 246 Million Series A Financing 14102 1PharmAbcine Closes USD 246 Million Series A Financing 14102 2PharmAbcine Closes USD 246 Million Series A Financing 14102 3PharmAbcine Closes USD 246 Million Series A Financing 14102 4
...ME TSX: COM, VANCOUVER and DEERFIELD, IL, June 04,...p. and its,co-development partner Astellas Pharma ... their recently completed Phase 3 clinical,study, ... safety of,the intravenous formulation of vernakal...atment of patients who developed,atrial fibrillati...
...ent Ever to Demonstrate Significant Survival Benef...wswire-FirstCall/ -- Bayer,HealthCare Pharmaceutic...unced that Nexavar(R) (sorafenib) tablets signific...epatocellular carcinoma,(HCC), or primary liver ca...p-value=0.0006). Results were presented at the 43r...
Other Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7
(Date:11/23/2009)... high cost of drug advertising that does little to...iversity of British Columbia health policy researc...ves of Internal Medicine , examined the US sales p...own by the trade name Plavix used to prevent blood...selected to study the impact of advertising on sal...
(Date:11/23/2009)... from women,s hair loss for almost ten years, Zsan...ng her progress and the secret behind her success ...of her video diaries which include a direct compar... , (PRWeb UK) November 23,...klosi has released the video diaries that document...
(Date:11/23/2009)...se the problem, researchers say , , MOND...their anger over unfair treatment at work could be...es. , Men who consistently failed to express th... or supervisor were more than twice as likely to h...e who vented their anger, claims a report in the N...
(Date:11/23/2009)...stCall/--InfoLogix,Inc.(Nasdaq: IFLG ),aleadingtec...healthcareandcommercialindustries,announcedtodayth...mensHealthServices,hasjoinedInfoLogixasVicePreside...://www.newscom.com/cgi-bin/prnh/20090618/NE35135LO...vicesforInfoLogix,Mr.Waywillberesponsiblefortheful...
(Date:11/23/2009)...wswire/--TheAmericanSocietyofHematology(ASH)andSch...dmediacompany,arelaunching"ExploretheMysteryofBloo...tinthefieldsofscienceandmedicine,inadditiontoexpos...gy. ,, "Manyhematologistsmayrememberwatchingaca...elearningaboutbloodreallyfun,"statedNancyBerliner,...
Breaking Medicine News(10 mins):Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3
...4 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ...hmias, announced today the publication of a Europe...ith CryoCor,s Cardiac Cryoablation System.,The pur...cused on isolating the pulmonary veins to treat th...
...utes of counseling helped people cut down on exces... -- Even a little counseling on the dangers of alc...n help problem drinkers cut back by at least three...t to almost 7,800 emergency patients in 14 univers...
...Jan. 2 Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that it has received final approval fr...ration (FDA) on its Abbreviated,New Drug Applicati...Sulfate product is the,generic equivalent to Dey, ...
...Jan. 2 Barr Pharmaceuticals,Inc. (NYSE: BRL ) to...es,Inc. has received final approval from the U.S. ... version of Roche Laboratories Inc.,s KYTRIL(R),(g...8, 2007, and plans to launch its product shortly.,...
... Mo. An estimated 750,000 hospitalized patients ..., and less than 30 percent of those leave the hosp...3 issue of the New England Journal of Medicine, re...c arrest known as ventricular arrhythmia. They fou...
...ncludes special deal and free unique support chann...YSE: MED ) today announced that the Company is of...closed Pure Weight Loss centers. Medifast is,offer...fast is also offering former Pure Weight Loss clie...
Other Medicine News:Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 2Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 3Health News:Brief Chat With ER Docs Can Curb Problem Drinking 2Health News:Watson Receives FDA Approval for Generic DuoNeb(R) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 2Health News:Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base) 3Health News:For hospital patients, defibrillation delays mean lower survival 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 2Health News:Medifast Offers Stranded Pure Weight Loss Clients Unique Options 3
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: